Billion-dollar drugs' makers set to face their first US price negotiations

Some of the most widely used drugs in the U.S. may be heading for lower prices under Medicare, a move that could save taxpayers billions of dollars and squeeze profits for big pharmaceutical companies.

Related Keywords

White House ,District Of Columbia ,United States ,Bristol Sotyktu ,Evan David Seigerman ,Johnson Xarelto ,Juliette Cubanski ,Spencer Perlman ,Fiona Rutherford ,Kamala Harris ,Joe Biden ,Angel Adegbesan ,Madison Muller ,John Tozzi ,Robert Davis ,Bristol Opdivo ,Supreme Court ,Congressional Budget Office ,Us Chamber ,United Astrazeneca Plc ,Tribune Content Agency ,Eli Lilly Co ,Cowen Co ,Bristol Myers Squibb Co ,Goldman Sachs ,Nacha Cattan ,President Joe Biden ,Inflation Reduction ,Eli Lilly ,Wells Fargo ,Bristol Myers Squibb ,Vice President Kamala ,Bloomberg Intelligence ,Chief Executive Officer Robert Davis ,Kingdom Based Astrazeneca Plc ,